OncRef

Clinical Trial: NCT03915951

An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

Status:

COMPLETED

Phase:

Phase 2

Lead Sponsor:Pfizer
Information Provided By:Pfizer
Last Update Posted:2026-03-24

Study Overview

Brief Summary

This is an open-label, multicenter, non-randomized, Phase 2 study to determine the safety, tolerability and efficacy of encorafenib given in combination with binimetinib in patients with BRAFV600E-mutant metastatic non-small cell lung cancer (NSCLC). Patients who are either treatment-naïve, OR who have received 1) first-line treatment with standard platinum-based chemotherapy, OR 2) first-line treatment with an anti-programmed cell death protein 1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) inhibitor given alone or in combination with platinum-based chemotherapy will be enrolled.

Official Title

A Phase 2, Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

Conditions

Non-small Cell Lung Cancer

Intervention / Treatment

  • Drug: encorafenib
  • Drug: binimetinib

Other Study ID Numbers

  • ARRAY-818-202
  • C4221008; PHAROS
  • 2024-515929-28-00

Start Date (Actual)

2019-06-04

Primary Completion Date (Actual)

2022-09-22

Study Completion Date (Actual)

2025-10-03

Enrollment (Actual)

98

Study Type

Interventional

Phase

Phase 2